

Perampanel Prescribing Guidance

Document history:

Version	Date	Main Changes/Comments
1	June 2022	Adapted from the 2014 East Kent prescribing group Perampanel Prescribing Information Sheet. Contact details removed and information that is duplicated in summary of product characteristics removed. Age range amended as per SPC.
1.1	July 2022	Amended to include minor changes to the indication section and information on MHRA warnings for risk of suicidal thoughts and behavior, switching between different manufacturers products and pregnancy following comments from Specialists.

Produced in consultation with:

Trudy Thomas	Epilepsy Specialist Pharmacist, Medway NHS Trust

Specialist Initiated Drugs

Perampanel

May 2022

Perampanel (Fycompa®)

Licensed Indications:^[1]

Fycompa (perampanel) is indicated for the adjunctive treatment of

- Focal seizures with or without secondarily generalised seizures in patients from 4 years of age and older.
- primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age and older

Formulations available on Formulary as Specialist Initiation Only

Film coated tablets available in 2mg, 4mg, 6mg, 8mg, 10mg, 12mg

Prescribing

Initiation:

Perampanel should be initiated by a specialist who will prescribe the initial supply.

The specialist will advise on titration of the dose according to individual patient response, in order to optimise the balance between efficacy and tolerability and until the patient is stable. This usually takes 1-2 months but will vary per patient.

The specialist should prescribe the most appropriate formulation and strength according to weight and dose.

Continuation:

On-going prescribing can be undertaken by a GP.

The responsibility for increasing/decreasing the dose or stopping treatment due to lack of effect or side effects remains with the specialist. They should be consulted if a change in treatment is required.

Specialist services should respond to **urgent** queries from primary care prescribers within 48 hours.

Abuse potential

Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of perampanel abuse^[1].

Risk of suicidal thoughts and behaviour

Antiepileptic treatment is associated with a small risk of suicidal thoughts and behavior. Patients and caregivers of patients should be alert to any mood changes, distressing thoughts, or feelings about suicide or harming themselves at any point during treatment and should be advised to seek medical advice should any signs emerge^[2]. Please see MHRA advice available [here](#)

Advice on switching between different manufacturers' products:

Perampanel has been classified as an MHRA category 2 drug in the three risk-based categories of antiepileptic drugs^[3]. Further information is available [here](#)

Patients may need to be maintained on a specific manufacturer's branded or generic perampanel product^[4]. Base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.

Also take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient.

MHRA advice: [Antiepileptic drugs in pregnancy](#)

There are limited amounts of data from the use of perampanel in pregnant women and the manufacturer currently states Fycompa is not recommended during pregnancy.^[1]

Any woman of child bearing potential or planning a pregnancy whilst on this drug should be referred for specialist review.

For additional information please see the Summary of Product Characteristics

<https://www.medicines.org.uk/emc/medicine/26951#gref>

References

[1] Summary of Product Characteristics Fycompa[®], Eisai Ltd. updated 07/2021

Approved by July JPC Ratified by Kate Langford

Ratified Date: Aug 2022

Review Date: Aug 2024

[2] MHRA Drug Safety Update, Antiepileptics: risk of suicidal thoughts and behaviour, published 2014.

[3] MHRA Drug Safety Update, Antiepileptic drugs: updated advice on switching between different manufacturers' products, published 2017

[4]BNF online, Perampanel Monograph, accessed 30/06/2022

[5] East Kent prescribing Group 'Perampanel prescribing information sheet' June 2014

Approved by July JPC Ratified by Kate Langford

Ratified Date: Aug 2022

Review Date: Aug 2024